RNA editing is emerging as a powerful tool and therapeutic modality, with Wave Life Sciences announcing positive clinical data for AATD, and a new wave of companies entering the clinic; the aspiration of bringing efficacious editors to patients is ever closer to becoming a reality. With the forging of important partnerships like Roche and Ascidian, and significant funding rounds like AIRNA's $155m oversubscribed series B, the 6th RNA Editing Summit couldn't come at a better time, returning to Boston this July to advance the discovery and development of RNA modifying therapies. Uniting 60+ RNA editing leaders from the likes of Korro Bio, Shape Therapeutics, Deep Genomics, HuidaGene Therapeutics, and more, this intimate, focused forum will showcase novel, innovative editing technologies, translational and functional biology, and never-before-seen clinical data.